Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Androxal shows noninferiority to Androgel in phase III interim analysis

Dec. 27, 2006

Preliminary topline phase III results for PolyHeme

Dec. 27, 2006

Clinical snapshots: cancer-related anemia, immune thrombocytopenic purpura

Dec. 27, 2006

Recent patents report new treatments for metabolic disorders

Dec. 22, 2006

Safety and pharmacodynamics of SB-559448 reported in healthy subjects

Dec. 22, 2006

European CHMP recommends use of Actos with insulin in type 2 diabetes

Dec. 21, 2006

Phenoptin demonstrates safety and efficacy in PKU patients

Dec. 21, 2006

New therapeutic agents for endocrine-related disorders imparted in recent patent literature

Dec. 21, 2006

Speedel stops phase III study of SPP-301 in diabetic nephropathy over safety

Dec. 21, 2006

Novel oral chaperones with potential use in Gaucher's disease

Dec. 21, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...